NYKD: Nykode Therapeutics to Showcase APC-Targeted DNA Vaccine Platform at 3rd Annual Personalized Cancer Vaccine Summit
2026-11-19 14:30:00
Oslo, Norway, November 19, 2026 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of cancer vaccines, today announced that Chief Executive Officer,
Michael Engsig, and Chief Scientific Officer and Co-founder, Agnete Fredriksen,
will participate in the 3rd Annual Personalized Cancer Vaccine Summit, taking
place December 1-3, 2026 in Boston, MA.
Nykode's leadership will contribute to three sessions during the summit, sharing
the company's perspectives on the development, manufacturing, and clinical
translation of personalized cancer vaccines.
"As interest in the field of individualized neoantigen cancer vaccines continues
to grow, attention is increasingly turning to how these treatments can be
delivered to patients at scale," said Agnete Fredriksen, Chief Scientific
Officer and Co-founder of Nykode Therapeutics. "We believe our APC-targeted DNA
platform offers a differentiated approach, supported by encouraging clinical
immunogenicity data and an established manufacturing process. We look forward to
contributing to discussions on the opportunities and challenges shaping the
future of personalized cancer vaccines."
Nykode's work in personalized cancer vaccines is being advanced through
VB10.NEO, its wholly owned, DNA-based individualized neoantigen therapy (INT).
Built on Nykode's proprietary antigen-presenting cell (APC)-targeting technology
and NeoSELECTTM, its AI-driven neoantigen selection engine, VB10.NEO is designed
to deliver selected antigens to APCs to generate broad, potent, and long-lasting
antigen-specific immune responses.
The company has established an end-to-end manufacturing process for VB10.NEO,
achieving 100% manufacturing success across two clinical trials. Further
optimization of the manufacturing process reduces the current turnaround-time
from biopsy to product release to less than six weeks with a clear path to
further reductions by additional consolidation under "one roof". Its plasmid
DNA-based platform also offers potential advantages in manufacturing complexity,
and cost of goods compared with alternative approaches.
Clinical data across two trials in patients with advanced solid tumors have
demonstrated vaccine-specific immune responses in 88-100% of patients, including
de novo T-cell responses in 85% of patients. These responses remained durable
for more than one year after the final dose, supporting the potential of
Nykode's platform to generate strong and sustained immune responses.
Summit Program and Presentation Details
1. Workshop: Streamlining Manufacturing, Analytics & Supply Chain Operations to
Accelerate Delivery of Personalized Cancer Vaccines
Speaker: Michael Engsig
Date: Tuesday, December 1, 2026
Time: 9:00 a.m.
2. Seminar: From Promise to Practice: Enabling the Next Generation of
Personalized Cancer Vaccines
Speaker: Agnete Fredriksen
Date: Thursday, December 3, 2026
Time: 9:00 a.m.
3. Panel Discussion: Comparing Personalized vs. Off-the-Shelf Cancer Vaccines to
Choose the Right Strategy for the Right Indication
Panelist: Agnete Fredriksen
Date: Thursday, December 3, 2026
Time: 11:30 a.m.
About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies with a focus on the
treatment of cancer and autoimmune diseases. Nykode's modular immunotherapy
technology specifically targets antigens to antigen presenting cells (APC),
which have been shown to induce a broad, strong and long-lasting antigen
specific immune response in cancer, which correlates with clinical responses.
Nykode's lead product candidates are abi-suva, a therapeutic immunotherapy for
the treatment of HPV16 induced malignancies which demonstrated favorable safety
and efficacy results from its Phase 2 trial for the treatment of late-line r/m
cervical cancer. Abi-suva is currently being further developed in first line
head and neck cancer with the randomized Abili-T trial with interim results
within 2027. VB10.NEO, an individualized cancer vaccine, has been investigated
in two trials with more than 10 different indications.
Nykode is also utilizing its APC-targeted technology to create an immune
tolerance platform for the potential use in autoimmune disorders, organ
transplant rejections, anti-drug antibody reactions and allergy.
Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD).
Further information about Nykode Therapeutics can be found at
http://www.nykode.com.
Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by these forward-looking statements.
Contact for Nykode Therapeutics ASA:
IR@nykode.com
Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway
ments.\
\
Contact for Nykode Therapeutics ASA:\
IR@nykode.com\
\
Nykode Therapeutics ASA\
Oslo Science Park\
Gaustadalléen 21\
N-0349 Oslo\, Norway\